Clinical trial · Interventional
Optical Coherence Tomography Guided C&D
Using OCT Imaging to Determine the Presence of Residual Tumor Cells After C&D for Superficial and Nodular BCC: A Prospective Study.
NCT04510727CI-TRIAL-00074168withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): device not available to initiate study.
Summary
Brief summary (as posted)
The purpose of the study is to identify the presence of residual superficial and nodular basal cell carcinoma (BCC) status-post curettage and desiccation (C\&D) by using optical coherence tomography (OCT).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Basal Cell Carcinoma | Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Curettage & Desiccation (C&D) Procedure | Procedure | — | UNRESOLVED |
| Optical Coherence Tomography (OCT) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- OCT Guided C&D Group
- description
- Participants in this group will receive OCT imaging immediately prior, immediately after and 2 months after post standard of care C\&D.
- interventionNames
- Device: Optical Coherence Tomography (OCT)
- Procedure: Curettage & Desiccation (C&D) Procedure
Primary outcomes (1)
- measure
- The incidence of residual basal cell carcinoma tumor cells
- timeFrame
- 2 months (post C&D procedure)
- description
- The incidence of residual superficial and nodular basal cell carcinoma tumor cells after standard of care C\&D as assessed using the OCT.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients of any: age, gender, Fitzpatrick skin type and ethnicity. * Primary BCC of any type, except aggressive types that fit the criteria for Mohs surgery * No prior treatment on the lesion within the last 3 months. * Lesions anywhere except the head, neck and distal extremities. * Willing and able to sign informed consent Exclusion Criteria: * Aggressive BCC types. * Recurrent tumors. * Lesion treated within last 3 months. * Lesions on head and neck (high risk areas) * Lesions on distal extremities (thin epidermis not preferred for OCT). * Pregnant women. * Patients less than 18 years old. * Prisoners. * Any other condition or circumstance that, in the opinion of the Investigator, may compromise the subject's ability to comply with the study protocol
References
Publications (0)
Data not yet available
No reference posted for this study.